Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

CardioProtectMI

financed

Closed

A New Drug Therapy for the treatment of ST Elevated Myocardial Infarction

Ischaemic heart disease (IHD) is the leading cause of mortality in Europe with about 1.8 million reported deaths per year in Europe alone. A serious consequence of IHD can be stopping blood flow to the heart causing a Myocardial I... see more

29/02/2020

RESOTHER PHARMA A/...

71K€

Project Budget: 71K€

Project leader

RESOTHER PHARMA AS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 2 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2020-02-29

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada does 5 years

0% 70% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

RESOTHER PHARMA A/S

50.00K€ | Leader

VERBIO TECHNOLOGIES

395.27K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 3 months Date Start: 2019-11-29
End date: 2020-02-29

Project leader

RESOTHER PHARMA AS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 71K€

participation deadline Sin fecha límite de participación.

Project description Ischaemic heart disease (IHD) is the leading cause of mortality in Europe with about 1.8 million reported deaths per year in Europe alone. A serious consequence of IHD can be stopping blood flow to the heart causing a Myocardial Infarction (MI). In the most severe cases this has a mortality rate between 6% and 14%. Clinical guidelines recommend immediate restoration of the blood flow via reperfusion therapy. However, this procedure results in high acute mortality (10%) and a significant incidence of congestive heart failure (12%) due to inflammation and ensuing cell death of the myocardial tissues. Current treatments do not provide a cardio-protective effect to mitigate this. Several potential therapies have emerged as promising cardio-protective therapeutic strategies for severe cases of MI, but up to date these have all failed to prove efficacy in later stages of human clinical trials. ResoTher Pharma ApS is a biotechnology company focused on developing a new class of therapeutics targeting the resolution of inflammatory responses. The company´s first drug candidate is a novel peptide with unique cardio-protective capabilities. Results from animal models reveal promising tissue-protective effects - decreases in myocardial damage related to the reperfusion injury (52%) and an overall improvement of the survival rate after an MI (up to 400%). The clinical validation of the lead drug will be key to demonstrate safety and efficacy in humans and allow ResoTher to establish itself in the chronic inflammatory disease market. The present SMEi Phase 1 will be of utmost importance to engage key stakeholders and prepare the clinical development plan in readiness for implementation during the Innovation Project. The clinical validation of the lead drug will lead to a significant business opportunity for ResoTher, supporting the company´s medium term strategic positioning as a unique provider of a new generation of anti-inflammatory drugs.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers